Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Outpaces Other International Drug Players In High-speed Growth In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Boosted by China's ever-expanding economy and ongoing health reforms, part of which are aimed at covering 90 percent of the country's 1.3 billion citizens with minimal medical insurance by 2011, drug firms posted an average sales growth rate of 27 percent in 2009, according to the global information provider IMS Health
Advertisement

Related Content

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
Market Rumors Grow On Potential GSK Purchase Of Nanjing MeiRui Pharma For Urology Expansion In China
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List
Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)
Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus
Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus
Advertisement
UsernamePublicRestriction

Register

SC075857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel